Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA.

Zhao J, Giles BM, Taylor RL, Yette GA, Lough KM, Ng HL, Abraham LJ, Wu H, Kelly JA, Glenn SB, Adler AJ, Williams AH, Comeau ME, Ziegler JT, Marion M, Alarcón-Riquelme ME; BIOLUPUS and GENLES Networks, Alarcón GS, Anaya JM, Bae SC, Kim D, Lee HS, Criswell LA, Freedman BI, Gilkeson GS, Guthridge JM, Jacob CO, James JA, Kamen DL, Merrill JT, Sivils KM, Niewold TB, Petri MA, Ramsey-Goldman R, Reveille JD, Scofield RH, Stevens AM, Vilá LM, Vyse TJ, Kaufman KM, Harley JB, Langefeld CD, Gaffney PM, Brown EE, Edberg JC, Kimberly RP, Ulgiati D, Tsao BP, Boackle SA.

Ann Rheum Dis. 2016 Jan;75(1):242-52. doi: 10.1136/annrheumdis-2014-205584. Epub 2014 Sep 1.

2.

Massive mobilization of dendritic cells during influenza A virus subtype H5N1 infection of nonhuman primates.

Soloff AC, Bissel SJ, Junecko BF, Giles BM, Reinhart TA, Ross TM, Barratt-Boyes SM.

J Infect Dis. 2014 Jun 15;209(12):2012-6. doi: 10.1093/infdis/jiu009. Epub 2014 Jan 7.

3.

Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus.

Giles BM, Boackle SA.

Immunol Res. 2013 Mar;55(1-3):10-21. doi: 10.1007/s12026-012-8345-z. Review.

4.

A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.

Giles BM, Crevar CJ, Carter DM, Bissel SJ, Schultz-Cherry S, Wiley CA, Ross TM.

J Infect Dis. 2012 May 15;205(10):1562-70. doi: 10.1093/infdis/jis232. Epub 2012 Mar 23.

5.

Computationally optimized antigens to overcome influenza viral diversity.

Giles BM, Ross TM.

Expert Rev Vaccines. 2012 Mar;11(3):267-9. doi: 10.1586/erv.12.3. No abstract available.

PMID:
22380818
6.

Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines.

Giles BM, Bissel SJ, Dealmeida DR, Wiley CA, Ross TM.

Clin Vaccine Immunol. 2012 Feb;19(2):128-39. doi: 10.1128/CVI.05533-11. Epub 2011 Dec 21.

7.

Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice.

Giles BM, Bissel SJ, Craigo JK, Dealmeida DR, Wiley CA, Tumpey TM, Ross TM.

J Virol. 2012 Feb;86(3):1500-13. doi: 10.1128/JVI.06034-11. Epub 2011 Nov 30.

8.

Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice.

Schneider-Ohrum K, Giles BM, Weirback HK, Williams BL, DeAlmeida DR, Ross TM.

Vaccine. 2011 Nov 8;29(48):9081-92. doi: 10.1016/j.vaccine.2011.09.051. Epub 2011 Sep 28.

PMID:
21963872
9.

Acute murine H5N1 influenza A encephalitis.

Bissel SJ, Giles BM, Wang G, Olevian DC, Ross TM, Wiley CA.

Brain Pathol. 2012 Mar;22(2):150-8. doi: 10.1111/j.1750-3639.2011.00514.x. Epub 2011 Sep 15.

10.

A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets.

Giles BM, Ross TM.

Vaccine. 2011 Apr 5;29(16):3043-54. doi: 10.1016/j.vaccine.2011.01.100. Epub 2011 Feb 12.

11.

Seroprevalence following the second wave of Pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA.

Zimmer SM, Crevar CJ, Carter DM, Stark JH, Giles BM, Zimmerman RK, Ostroff SM, Lee BY, Burke DS, Ross TM.

PLoS One. 2010 Jul 14;5(7):e11601. doi: 10.1371/journal.pone.0011601.

12.

Augmentation of NZB autoimmune phenotypes by the Sle1c murine lupus susceptibility interval.

Giles BM, Tchepeleva SN, Kachinski JJ, Ruff K, Croker BP, Morel L, Boackle SA.

J Immunol. 2007 Apr 1;178(7):4667-75.

Supplemental Content

Loading ...
Support Center